June 7, 2015Open Access
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Key Points
Key points are not available for this paper at this time.
Abstract
As adjunct to insulin, dual SGLT1 and SGLT2 inhibition with sotagliflozin improved glycemic control and the CGM profile with bolus insulin dose reduction, weight loss, and no increased hypoglycemia in type 1 diabetes.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Sands et al. (Sun,) studied this question.
synapsesocial.com/papers/69d76887447a5ff6a2b8a70d — DOI: https://doi.org/10.2337/dc14-2806
Authors
A
Arthur Sands
Nurix (United States)
B
Brian Zambrowicz
Regeneron (United States)
Julio Rosenstock
General / Preventive / Lipids
Journals
Diabetes Care
Actions
Institutions
University of North Carolina at Chapel Hill
University of Colorado Denver
Albert Einstein College of Medicine
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...